My #1 Takeover Target for May

The Ultimate Investing Test

But what if you could see the results first? See if they really lived up to the hype.

You could check the claims directly against the truth... this way, you could judge the performance for yourself - in black and white.

The best part is, you wouldn’t have to pay for it, so you’d truly have absolutely nothing to lose.

Well several years ago, a select group of our customers were given that chance when Dylan Jovine, the former owner of Wall Street investment bank Lexington Capital Partners, began picking takeovers.

And the results spoke for themselves...

97 Winning Takeover Picks...
With Over a 90% Success Rate

Incredible, right?

When Dylan recommended shares of Telephone & Data Systems... it soared 100% after T-Mobile announced its acquisition.

When he recommended Agio Pharmaceutical options... they soared 142% on takeover news.

When he recommended Loxo Oncology... 3 days later it was taken over for a 71% gain...

When he recommended shares of Tesaro... 63 days later it was taken over for a 91% profit.

He took 182% profits on Array Biopharma after Pfizer bought it.

And U.S. Steel jumped 58% on the Nippon Steel takeover deal.

What are the secrets to Dylan’s incredible success picking takeovers?

He would like to tell you himself...

Welcome to Takeover Targets

Dear Friend,

My name is Dylan Jovine.

I’m a professional investor. What I mean by “professional” is that I don’t get paid a yearly salary to do my job.

As the former owner of a Wall Street investment bank, my yearly pay was based on one thing and one thing alone…

My investment performance.

If I picked more winners for the year than losers, I earned money. If I picked more losers than winners, I didn’t make much.

Thankfully, I’ve made a lot of money for myself and for those who follow my advice. And that’s why I’m so confident in the biotech stock I’m going to tell you about today…

And why it’s such an exciting time to be buying takeovers in the biotech sector!

The Next Biotech that I Believe Gets Taken Over

Today I’m going to take you behind the scenes and introduce you to a company ripe for takeover...

Because they won FDA approval on their breakthrough therapy that uses a patient’s own immune cells to attack melanoma on a genetic level — transforming how that disease is being treated.

And not just melanoma. The same platform is now showing stunning results against lung cancer, endometrial cancer, and sarcoma — with clinical trials underway that could expand its reach to some of the deadliest solid tumors on earth.

1 Treatment Platform that Could Stop 7 Different Cancers

Now look, I get it. It sounds hard to believe….

But once we explain the science behind this medical breakthrough, you’ll see why Big Pharma has spent over $228 billion on biotech acquisitions in the past year alone.

We’ll dive into all of that shortly. But I want to say something first. I want to be clear about something before we continue:

You don’t have to be a scientist or doctor to invest in this company or understand why it’s so valuable.

There are a lot of research services out there that try to make investing way more complex than it needs to be.

Maybe they think that confusing you will make them seem smart.

That’s not how we do things around here. It’s not my style.

I’m going to give it to you straight. Here it is:

There are a few key things you need to understand about this opportunity - and that’s what we’ll be focusing on today.

And because this may be the first takeover you ever own, I want to spend a moment to go over three key concepts first...

I’ve been doing this for over 30 years. Over 30 years is a long time to be doing something.

3 Key Ingredients to Any Takeover Deal

During the past three decades, I’ve developed a set of rules to identify the stocks most likely to get taken over the fastest.

It’s why I’ve picked so many takeovers throughout my career. In fact, it’s how I made a name for myself on Wall Street.

Takeovers like Array Biopharma up 182%... Loxo Oncology up 72%... Tesaro up 91%... U.S. Steel up 58% and Telephone & Data Systems up 100%.

That’s 97 winning takeover plays — with over a 90% success rate.

And that’s just recently. Over the past three decades, it’s been more.

How do I pick these?

It’s because I owned a Wall Street investment bank called Lexington Capital Partners.

And what I learned is that there are three key ingredients to any good deal.

How important are these three ingredients I’m about to tell you about?

They’ve helped me pick every takeover I’ve ever owned.

And to be clear, you can use them to help YOU evaluate any takeover opportunity. NOT just this one.

Oh, and you may want to grab a pen before we continue so you can write these down.

Again, you’ll be able to use these Three Key Ingredients to Any Good Deal when you’re evaluating other takeovers down the road.

Ingredient #1: A Large Gap Between the Value of a Company and What the Common Stock is Selling for

Ok, so ingredient #1 is a large gap between the value of a company and what the common stock is selling for.

Let me repeat that–the first ingredient you need is a large gap between the value of the company and what the common stock is selling for.

Some of you reading this may recall that we recommended Array Biopharma originally at $17.05 a share.

Now Array stock was selling for $17.05. But we believed the company was worth close to $50 a share.

And this is something I need everyone reading right now to understand.

There’s a big difference between the value of a business and what the common stock is selling for.

That’s why when a deal was announced, we made 148% in one morning with Array!

The Biggest Mistake Investors Make

And that’s the biggest mistake most investors make – they think the price a stock is selling for is what the actual business is worth.

But that’s mistaken.

A stock price could either–

• MATCH what the actual value of the business is worth...
• BE GREATER THAN what the actual business is worth...
• BE LESS THAN what the underlying business is worth...

That’s my point: what a stock is selling for doesn’t tell you what the underlying business is actually worth. Those are two entirely separate things.

For example, according to JD Power & Associates the Lexus ES was the most reliable car in the world for 2021.

But what is it worth?

Would you pay $1 million for the BEST MOST reliable car in the world?

No, you wouldn’t. Why? Because at $1 million it’s selling for more than it’s worth.

But I bet you’d buy it for $1,000.

Of course you would. Why? Because its selling for less than its worth.

And by the way the MSRP is $39,750.

Same thing with Array.

Array Stock was Selling for $17.05 but the Business was Worth $50

In other words, we disagreed with the list price of the stock price.

We thought Wall Street didn’t understand what the underlying business was worth.

It’s like we were able to buy that Lexus for 70% off the sticker price.

And you already know what happened –

Array was taken over by Pfizer for $48 a share for an easy 182% profit.

And that’s my point.

What a stock is worth and what it actually sells for are two very different things.

Ok, now we’ll move onto our second ingredient.

Ingredient #2: You Need a Board of Directors Open to a Legitimate Offer.

Ok, we originally recommended Loxo Oncology at $131 a share on Friday, January 4th of 2019.

Now Loxo had a board of directors that were open to a deal.

The CEO of Loxo was a healthcare banker on Wall Street. The COO came from Goldman Sachs.

Basically, these guys were born and bred to do deals. That’s what they do. That’s why...

Contrast that with the company founded by a builder. A real CEO who scratched in the dirt and fought with all his might for every penny the company made.

Somebody like Steve Jobs. A real entrepreneur. A builder.

This guy wasn’t looking to make a quick buck turning a company around and selling it.

This guy was trying to change the world.

My point is that if you don’t have a board of directors open to an offer, you’re rarely going to get a deal.

And let me tell you I have it on good authority that Steve Jobs rejected a couple of takeover offers when he took back control of Apple.

Entrepreneurs like that are not going to sell a company unless they’re forced to.

Ok, and finally Ingredient #3 –

Ingredient #3: You Need Potential Buyers.

We recommended Tesaro stock at $38 on October 1st, 2018. And it was taken over by Glaxo 63 days later for a 91% gain.

Just like today’s company, Tesaro also developed a platform treatment. It too was for cancer.

And that got Big Pharma’s attention. They believed this new platform would treat not just one form of cancer but several.

Glaxo snagged them first.

So there were buyers lining up.

The question was not “Is there a buyer or not?”...

The question was “Who was going to buy Tesaro first?”

Potential Acquirers

That’s the position we want to be in when looking for takeovers.

We want to own stock in a company that has such a game-changing product or treatment that all big competitors are licking their chops.

It could be the greatest company in the world. But if nobody wants to buy the company it’s not going to get taken over.

That’s why we’re so excited about today’s company.

It has each of the 3 key ingredients to a deal: a large gap between the value of the company and what the common stock is selling for, a board of directors open to a legitimate offer, and potential buyers.

And that’s why the timing is so good right now. Things are lined up really well for this deal to go down.

A deal that can hand you returns of 300 - 800% any day.

Today’s Takeover Target Invented a New Way to Attack Cancer

Once again, what you’re looking at right now is an illustration of this company’s breakthrough cancer platform –

What makes it so exciting is that it uses a patient’s own fighter T-cells to attack solid tumors.

This causes tumors to shrink and die.

It was first discovered by an American scientist who’s been called “the father of cancer immunotherapy.”

He and his team were trying to find a new way to attack melanoma.

Something that uses our own body’s natural defenses against solid tumors.

Now all of you have heard of Chemotherapy. Maybe you know a loved one who has had to go through it. I know I have.

Well right now one of the most common drug classes for people diagnosed with advanced melanoma is checkpoint immunotherapy.

But here’s the problem: roughly half of all melanoma patients don’t respond to checkpoint drugs. And for those who do, many eventually stop responding.

Millions of Cancer Patients Still Have No Good Options!

Think about that for a moment...

Despite all the advances in cancer treatment, millions of patients with advanced solid tumors still run out of options. The drugs stop working. The cancer keeps spreading.

Come on. Most of you here with us today know what I’m talking about. Going through cancer treatment or watching a loved one go through it is brutal. Absolutely brutal.

This is what they mean by the expression “when the treatment stops working, you’re out of luck.”

Standard treatments are the “OLD WAY” of doing things.

Researchers Were Looking for a NEW WAY to Fight Melanoma

An approach that took advantage of what they had learned about the human immune system...

They wanted to invent treatments that harness a patient’s own immune cells to fight their specific cancer...

Because the old way of doing things is just to prescribe a one-size-fits-all drug and hope for the best.

But now we can harvest the very immune cells that have already infiltrated a patient’s tumor — the cells that are already trying to fight the cancer — multiply them by the billions in a lab, and infuse them back into the patient.

And today’s company does just that.

How?

They Discovered How to Attack Melanoma at the Cellular Level

It attacks melanoma in a completely new way.

What they learned is that you can take a patient’s own tumor-infiltrating immune cells, grow them into a powerful army, and unleash them to kill cancer cells.

And as Fierce Biotech noted, it’s —

"One of the most effective forms of personalized cancer care…"

And the FDA agreed. This company won full FDA approval — becoming the first and only approved T cell therapy for a solid tumor in history.

That means real lives are being saved. Over 1,500 patients have already been treated. Maybe someone we even know or love.

But that’s just part of the story here.

The scientists then asked themselves another question “Are there other solid tumors this can work against?”

We already know it works with melanoma.

It’s Now Expanding Into Other Deadly Cancers

Could the same approach work with other solid tumors?

The short answer is yes. And the clinical data is already proving it. Let me explain:

It turns out that the same technology can be used to attack other solid tumors.

Cancers like -

By treating all these different types of cancer, this treatment platform can impact the lives of over a million people each year.

It’s Called a “Platform Technology”

That’s what we call a platform technology.

Instead of inventing one drug to treat one disease, they’ve invented one approach to treat multiple diseases…

The fact that this breakthrough is proving to be so effective across multiple cancer types is why this is such a game-changer.

Big Pharma Spent Over $228 Billion on Biotech Acquisitions Last Year

That’s because right now there’s a war being fought inside of your medicine cabinet. It’s a war being fought over people with cancer.

And the war is being fought by the biggest pharmaceutical companies in the world. They’re fighting each other over shelf space.

Why?

There is a War Being Fought Inside Your Medicine Cabinet

Because it’s very expensive to treat cancer. I know this from first-hand experience.

The average cost for cancer treatment is over $150,000 a year.

Unbelievable really.

But that’s how Big Pharma sees it: someone with cancer is worth, on average, $150,000+ a year.

Nearly 2 million people are diagnosed with cancer each year in the United States. This is big business. Very big business.

That’s why these companies are fighting so hard for a piece of your medicine cabinet.

It’s a $383 Billion+ Market!

As I mentioned, the company already has FDA approval for its melanoma therapy.

And it’s generating over $350 million in revenue this year alone — in just its second full year on the market.

But remember, this is a platform technology. It gives Big Pharma a bigger slice of the medicine cabinet.

That’s why Big Pharma has spent over $228 billion on biotech acquisitions in the past year — up 73% from the year before. And oncology remains the single most targeted therapeutic area.

According to Research and Markets, the solid tumor cancer market alone is expected to hit $383 billion by 2028.

That’s why Big Pharma is so interested.

There’s big money here.

And this is why we see a deal happening.

The Three Most Likely Buyers

You see, there are a handful of drug companies that are waging a war to get their medicines on the shelves of cancer patients.

Now Eli Lilly bought out Loxo Oncology, which we recommended, for their own cancer platform technology.

And Glaxo bought out Tesaro, which we recommended, for their own cancer platform technology.

And Pfizer bought out Array Biopharma, which we recommended, for their own cancer platform technology.

And just recently, Gilead paid $7.8 billion to acquire Arcellx — another cell therapy company — to bolster their cancer pipeline.

In my view, Merck is the most logical buyer.

Here’s why: Merck’s blockbuster cancer drug Keytruda generates over $25 billion a year. Our target company is running a major clinical trial combining its therapy with Keytruda. If Merck owns both, they control the entire treatment protocol.

But Gilead, Bristol-Myers Squibb, and Roche are all strong potential buyers too. Each has invested billions in oncology M&A and each would benefit enormously from owning this platform.

But whoever the final buyer turns out to be, the deal will likely look at the potential size of the opportunity.

And that’s how we made a fast 72% profit with Pacific Biosciences.

Remember, the entire solid tumor market is expected to be $383 billion by 2028.

This company is already generating $350+ million in revenue this year from melanoma alone.

Its lung cancer program addresses a market 7 times larger than melanoma. If approved, peak sales from just melanoma and lung cancer could exceed $5 billion a year.

And that doesn’t include endometrial cancer, sarcoma, colorectal, or breast cancer.

Oncology-focused biotech companies go for 3 – 5 times expected future peak sales in acquisition deals.

At 3 times peak sales of $5 billion, that’s a $15 billion deal.

At 5 times peak sales, it’s a $25 billion deal.

Chances are it’s right in the middle.

At the Low-End of the Range, That Would Be a 300% Return… …At the High-End of the Range, That Would Be an 800% Return…

Now I want everyone to pay attention right now because we’re about to go over something really important... so look, first and foremost, let me say this:

When it comes to takeovers, there’s always a risk that things don’t go as planned.

But let me tell you why I think this stock is a great buy whether or not a deal happens.

1. This company already has FDA approval and is generating hundreds of millions in revenue. It’s not a speculative startup — it’s a real business with a real product saving real lives.

   The company just raised its full-year 2026 revenue guidance to $350-$370 million. And it’s projecting a $1 billion peak sales trajectory in the U.S. alone — and that’s just from melanoma.

   In other words, this is NOT two guys in a lab testing mice.

2. On top of that, the company has put together a team of all-star managers to help bring its business to market.

   Top management includes veterans from some of the biggest drug companies on earth — including Pfizer, Bristol-Myers Squibb, Merck, Genentech, and Roche.

   In other words, this is a proven team who’s already created billions of shareholder value in the exact same industry that this company operates in.

3. On top of that, the company has secured FDA Fast Track designation for its lung cancer program and is running multiple registrational trials that could dramatically expand its market.

   The lung cancer market alone is 7X larger than melanoma. Early data in endometrial cancer shows a 40% response rate. And sarcoma data shows a 50% response rate.

That’s why we believe a deal could be announced any day…

A Deal Could be Announced Any Day

So to sum it all up...

Sure, any takeover target could not go through as planned...

But look at what this company has in place already -

These guys know what it takes to win.

We feel good about this company.

Now let’s look at everything we just discussed in the context of what we talked about in the beginning of today’s presentation.

Remember, we said that when we’re looking for takeover targets, we have to make sure the target has 3 things in place -

• A Large Gap Between the value of the company and what the common stock is actually selling for
• A board of directors open to a legitimate offer
• You need potential buyers.

Now let’s take these one at a time.

Ingredient #1 - A Large Gap Between the value of the company and what the common stock is actually selling for.

Remember what we said: oncology-focused biotech companies go for 3 – 5 times expected future peak sales.

With peak sales projected to reach $5 billion or more, we’re looking at a deal that could be worth 5 to 15 times the value of the entire company today.

The stock is trading under $4. We see a deal at $20 or higher.

That would hand investors a profit of 400 - 800% (or more) based on how we recommend playing it.

At the low end of the range, you could see a 300% return. At the high end of the range, you could see an 800% return.

Chances are it’s somewhere in the middle.

Ok onto ingredient #2...

Ingredient #2: A Board of Directors Open to a Legitimate Offer

The company actually explored a sale back in 2020, according to Bloomberg. That means the board has already been through the process.

On top of that, the company’s management team is stacked with executives from Pfizer, Bristol-Myers, Merck, Genentech, and Roche — people who have built companies and sold companies. They know how deals get done.

So, this team knows how to build companies and they know how to sell them. They’re deal makers.

And finally, you need ingredient #3: potential buyers.

As I mentioned earlier, Merck is the most logical buyer — they’re already running a joint clinical trial with our target company using their blockbuster drug Keytruda.

But Gilead just paid $7.8 billion for a cell therapy company. Bristol-Myers paid $4.1 billion for RayzeBio. These companies are spending billions to build out their cancer pipelines.

The question isn’t IF someone will want to buy this company. The question is WHO will buy it first.

But as we mentioned earlier, while I believe you can see a 500%+ return, things don’t always go as planned. That’s not the way the world works…

So even if a deal doesn’t happen, the company’s rapidly growing revenue and expanding drug pipeline will likely cause this company’s value to soar over the next 3 years…

This path could conservatively hand early investors like you 300% (or more) on your money.

It’ll just take longer.

Successfully Picking Takeovers for Over 30 Years

But look folks I’ve been picking takeovers for over 30 years. Some of my Wall Street clients helped me bankroll my brokerage firm Lexington Capital Partners.

In the Takeover Targets portfolio alone, we have 97 winning picks with over a 90% success rate.

Only a handful of times was the chance of a deal so high.

One was with American Railcar!

Just like today’s company, Greenbrier didn’t have much of a choice. They had to make a deal to buy the company and they had to do it fast.

If Greenbrier didn’t buy American Railcar, Burlington Northern could have seriously threatened Greenbrier’s business.

We made 51% gains when the deal was announced for $69.93.

Ok, and moving on, the last time I saw an opportunity like this was when Glaxo bought Tesaro in October 2018.

I mean Glaxo hired a new chief scientific officer who publicly said they wanted to invest in oncology treatments that attack cancer at its DNA level.

There were only three companies that did that. But everything was pointing to Tesaro. Within 63 days of recommending it, the company was acquired.

Platform Cancer Biotechs Are Being Taken Over!

Dozens of biotechs with platform cancer therapies have been taken over by Big Pharma in the past several years.

On April 28, 2026, Gilead paid $7.8 billion for Arcellx — a cell therapy company. Merck has spent over $25 billion on acquisitions since 2024. AbbVie paid $10.1 billion for ImmunoGen. The list goes on and on.

That’s why we believe this company could potentially hand you profits of more than 500% any day.

That’s like waking up one morning to news of a takeover and turning $5,000 into $25,000... or $45,000...

This could be one of the fastest ways to make money that I’ve seen come around in a long time...

And that’s why we rushed to get this out to you– and why I’d like to invite 100 people along for the ride…

In order to help you make your decision about this company, we’ve prepared an in-depth 30-page Research Report on this rare opportunity...

Not only does this report review everything we’ve talked about today…

But it also provides:

• Company history
• Science behind the breakthrough
• In-depth profit analysis

And we’re giving this 30-page report away to 100 people, for FREE today.

In order to secure your copy, and give yourself the chance to claim your stake in this exclusive investment opportunity…

…all you need to do is accept our special invitation to join our VIP research service, Takeover Targets.

Takeover Targets is unlike any other service you’ve ever subscribed to before…

For one thing, we only publish research and recommendations around takeovers… opportunities like the one we’ve been telling you about today.

Which also means that this service is unique because it’ll give you the chance to earn much higher returns and much faster than average investments.

Again, as you’ve learned today, the reason most folks come up short in their investing is simple - they’ve been investing in the wrong places!

Average investment strategies give you average investment returns.

But by knowing how to invest in takeovers, you’ll give yourself the chance to earn potentially life-changing profits each and every month.

And when you become a member of Takeover Targets today, you’ll get that chance again and again...

That’s because after you join today and download “Our #1 Takeover Target this Month”, we’ll send you a new pick every single week.

Over the next year, you’ll receive as many as 48 takeover targets— ideas that could multiply your wealth many times over.

Our Minimum Target is 100% on this Deal

I don’t recommend anything unless you can double your money on it. Why would I? It’s a waste of time.

Now I know that some of the numbers we’re tossing around here — numbers like 500% your money or 800% on your money — they may sound hard to believe.

But here’s the thing...

I’ve been picking takeovers since 1992.

My clients invested the profits I made them into my brokerage firm.

So you’re not letting a rookie take you on a wild-goose chase.

Picking takeover targets is what I do…

That’s why we have 97 winning takeover plays with over a 90% success rate. That’s roughly one winner every 24 days, on average!

Now to be clear, most of these stocks weren’t on anybody else’s radar – but some good old-fashioned homework on my part brought my customers gains of 100%, 142% and even 58% on U.S. Steel – in as little as 4 days on some trades.

We’ve already helped hundreds of investors just like you...

But now it’s your turn.

Let me help you build a portfolio of solid takeover targets... Investments just like the one we’ve been telling you about today.

Again, after you join Takeover Targets, you’re going to begin receiving a new target each and every month…

It won’t be long before you’re well on your way to building a diversified portfolio of high-quality — and hopefully, highly-profitable — takeover targets.

And don’t forget, we’ve already helped hundreds of investors just like you do the exact same thing...

And as a Takeover Targets member, we’ll try to find the same types of deals for you every month...

In fact, we believe that the company we’ve been telling you about today could become our most profitable takeover target this year.

At the High-End Your Profits Could Reach 800%

Again, at the low-end of the range, you stand to earn a 300% return...

But at the high-end, your profits could reach 800%... and possibly far more.

It’s also worth mentioning that we have no incentive to try and “sell” you on making this investment...

We’re not acting as this company’s banker or broker, and it’s not compensating us in any way.

Behind the Markets is an independent provider of investment research. We don’t accept any compensation from the companies we write research on.

And I’m just telling you about a stock I believe is going to be acquired.

The Past Has Been Great … But the Future Looks Outstanding!

We all know that anybody can make money trading during strong bull markets. During the Roaring 1990’s, I saw traders make fortunes almost overnight.

But just as fast as that wealth came, it went: Many good people just weren’t experienced enough to handle the stove when the kitchen got too hot.

That’s why I can’t overstress this important fact: Bull markets are only here 20% of the time. That’s why the mark of a great trader is how much money they make during bear markets, flat markets or volatile markets.

Let me explain:

Since coming out of retirement in 2018, I’ve helped folks make money picking stocks in bull markets, bear markets and flat markets.

A few closed winners include:

• ✓GRAIL+461%
• ✓ImmunoGen+449%
• ✓Rocket Lab+503%
• ✓Palantir+408%
• ✓ChemoCentryx+301%
• ✓IonQ+257%
• ✓Krystal Biotech+242%
• ✓Viking Therapeutics+190%

But here’s the thing…

As remarkable as these gains are…

They don’t compare to what’s in front of us right now.

And while there will be a number of ways to profit in the coming years, there will not be an opportunity like the one before you today.

You see, the dawn of a new takeover age in biotech is upon us.

This is the very beginning.

Before today, what you lacked was “access.” Now, though, you have a chance to leverage my knowledge, experience, and contacts … even if you’re not a millionaire.

So let me get right to it and explain what you can expect to get from me when you join.

Every Issue is Very Short and to the Point...
Every Trade is Easy to Understand and Execute.

What would be the point if I gave you profitable advice and you couldn’t use it?

That’s why we’ve devised an ultra-simple system for our members.

Each week, all you have to do is four easy things:

1. 1Check your email on Thursday afternoon and review my half page recommendation. It will look something like this:
   “Trade of the week: I’m recommending you purchase shares of XYY. I think it trades north of $$ in 6 months. If filled at $$$, your maximum risk is $$ plus transaction costs. Your net potential profit is unlimited. Happy hunting!”
2. 2Decide if my recommendation is something you want to invest in (it’s completely up to you!).
3. 3Place your trade online or with your broker.
4. 4Wait for your profits to pile up and fatten your portfolio.

It was designed to be that simple on purpose. All in all, it may take you 5 minutes to execute each trade. And that’s all you have to do. Leave the hard work to me. Even if you don’t understand every aspect of our trades, that’s fine.

I will explain each and every move we make together as clearly as humanly possible. As my track record shows, you don’t have to worry about it.

Proven results... For About the Cost of a Grande Latte a Day!

When you join Takeover Targets, you’ll be joining a small and sophisticated group of investors who are ready to take advantage of some of the biggest profit opportunities this century.

When I see an opportunity come along that offers the “little guy” a chance to become a multi-millionaire simply by reading the contents of their email box each week – I can’t help but get excited!

That’s why you don’t need to invest $10,000 – or even $5,000 – the cost of “competing” services by people whose best ideas couldn’t generate the kinds of profits we’ve generated together already.

If you ask me, those people aren’t real traders, they’re entertainers who write for a living – they haven’t spent their entire careers getting paid by performance.

In fact, we’re pricing our service at just $2,997 per year. And if you’ll forgive me for being so direct, you won’t find a better value anywhere. It’s a whole heck of a lot less than my hedge fund clients pay... and you’ll be getting the very same quality of advice.

That’s only $8.20 per day for access to guidance that’s been reserved – until now – only for some of the richest people in the world.

But didn’t I just tell you that you’d be getting the service for the “cost of a Grande Latte a day?”

I’m glad you asked.

Since you’re a Behind the Markets customer, we decided to give you a very serious thank you bonus...

Your cost to join me in Takeover Targets: Discounted for 100 New Members Today

As I promised you, you’re getting the opportunity to be one of the very first members of Takeover Targets.

Also as I promised, you’re entitled to a discounted membership fee that – I can guarantee you – will likely never... ever... be offered to anyone else at any point in time.

And based on our past experience together, you and I both know that there’s a very good chance you’ll make that back on your first trade alone.

You helped make this all happen, and truly, I wanted to repay you in a very big way.

You Can Even Try it RISK FREE!

Also at my insistence, you have an ironclad guarantee of satisfaction.

At this stage of my life I’d prefer not to do business with people who don’t appreciate or understand what I do. I want to give you a fair and honest opportunity to take my service for a spin.

That means you can try Takeover Targets for 30 days on me. That’s four weekly issues. If you’re not happy with what you see – or you simply don’t think this kind of trading is for you – just contact customer service, tell them you want to cancel, and you’ll get a full refund.

No questions asked.

That’s what I mean by “fair and honest” try. If you’re not thrilled, every dime of your membership fee will be returned to you. You risk nothing.

I’m fully confident that, after just a few trades, you’ll see the profits begin to pile up. But it’s nice to know that there’s a no-risk guarantee, don’t you think? Just in case... for some reason... if this service just isn’t for you.

But there’s something else I want to pass on to you.

Something that may prove to be as valuable to you as any profitable trade we make together:

Your Free Bonus Report #1:

Our #1 Biotech Takeover Target for May

This in-depth report will give you all the details on the amazing biotech we just discussed in our presentation – and why we think it offers you a 500%+ return opportunity!

Value: $1,497

Your Free Bonus Report #2:

My “Key Code” System: How to Skim Extra Money Each Month From Takeovers

This rare presentation offers you an inside look at the technique I’ve used to pick so many takeover targets during the past thirty years!

Value: $997

Let me quickly recap what you can expect to get as a member of Takeover Targets:

• Unmatched Advice, Winning Recommendations:

  You’ll get the benefit of the best investment experience money can buy in 48 weekly issues (due to holidays) of Takeover Targets – e-mailed to your inbox every Thursday at 2:00pm Eastern. Once you get the email, simply call your broker or place your trade online. Value: $2,997

• FREE Bonus #1: “Our #1 Biotech Takeover Target for May”:

  This in-depth report will give you all the details on the amazing biotech company we just discussed in our presentation – and why we think it offers you a 500%+ return opportunity! Value: $1,497

• FREE Bonus #2: My “Key Code” System: How to Skim Extra Money Each Month from Takeovers:

  This rare presentation offers you an inside look at the technique I’ve used to pick so many takeover targets during the past thirty years! Value: $997

• 100% Money-Back Guarantee:

  Because I want you to profit from my advice without fear and without hesitation, I’m backing up my claims with an unconditional guarantee: Try Takeover Targets risk free. If you don’t like the service in the first 30 days for any reason whatsoever, every dime you paid toward your membership will be returned to you. The reports are yours to keep.

Whatever you do, don’t forget that, with your free bonus reports, you’ll immediately get…

6 Great Trades You Can Make Right Now

I’m serious about starting this relationship off on the right foot.

And while I’m 100% confident that I can help you become much richer through the specific, fast-paced, high profit recommendations I’ll be emailing you each week …

… Even if you don’t like the service, you’ll still have the free reports to keep – and the 6 trades that can bring you huge profits immediately.

And don’t forget, sometimes I like to trade very quickly – that means profits can happen very quickly as well.

You have to act fast if you want to make profits like the 72% with Pacific Biosciences…

Or the 71% gain taken from the trades we made with Loxo Oncology…

But most importantly, don’t miss this opportunity to get on board for much less than anyone will ever get it for again.

My point is, now is not the time to delay.

This is truly a trader’s market – one that will kill the uninitiated at the expense of the big-money professionals. With this kind of volatility, there’s an endless supply of money making-ideas opportunities being left on the table every day that a seasoned pro like myself is more than willing to pick up.

Not only can you make good profits, but the profits come fast and furious at times like these.

Only 100 Memberships Left Today!

Most other services don’t have membership limits. Those that do – usually the ones that only deal in thinly traded options – typically accept 5,000 people or so, because they don’t want too many people chasing the same trades and “moving the market.”

But I’ve insisted that we limit our total membership to only 500 people. And I’ve made this request for a much different reason than you might imagine… actually, two reasons:

First, as a brokerage firm owner for a small group of ultra-high net worth individuals, I’ve gotten used to moving quickly and quietly through different markets around the world.

And that’s an advantage I absolutely refuse to risk losing. If I allow too many people into this service… and am no longer able to move around the market “below the radar”… I fear I wouldn’t be able to deliver at the level you expect of me.

The second reason for this very strict limit on memberships is more personal.

When I first started my career on Wall Street, I couldn’t imagine anything being more important to my job satisfaction than the bottom line. I figured that the more money I made, the happier and more successful I’d be.

Now that I’m a bit older and quite a bit wiser, I’ve realized that there’s something that I value even more than the jingle-jangle of change in my pocket:

The feeling of family that’s developed between me and the people who trust me with their investments. It’s a huge responsibility, and one that I’ve been able to live up to. And I gotta tell you, it really hits home around the holidays when my clients and I exchange gifts.

This is the kind of feeling that I want to shoot for in Takeover Targets...

So, in short, that’s why I’m urging you to take advantage of this risk-free offer right now.

Your free special reports will follow in your inbox immediately.

I look forward to working for you and making money together.

Will you join me?

Click here and we’ll get started.

“The Buck Stops Here,”